Cardiovascular Research

Age-Dependent Metabolic and Immunosuppressive Effects of Tacrolimus.

Authors: F Krenzien|||M Quante|||T Heinbokel|||M Seyda|||K Minami|||H Uehara|||H R C Biefer|||J M Schuitenmaker|||S Gabardi|||K Splith|||M Schmelzle|||A K Petrides|||H Azuma|||J Pratschke|||X C Li|||A ElKhal|||S G Tullius

Affiliations: + Expand

Abstract

Immunosuppression in elderly recipients has been underappreciated in clinical trials. Here, we assessed age-specific effects of the calcineurin inhibitor tacrolimus (TAC) in a murine transplant model and assessed its clinical relevance on human T cells. Old recipient mice exhibited prolonged skin graft survival compared with young animals after TAC administration. More important, half of the TAC dose was sufficient in old mice to achieve comparable systemic trough levels. TAC administration was able to reduce proinflammatory interferon-γ cytokine production and promote interleukin-10 production in old CD4 T cells. In addition, TAC administration decreased interleukin-2 secretion in old CD4 T cells more effectively while inhibiting the proliferation of CD4 T cells in old mice. Both TAC-treated murine and human CD4 T cells demonstrated an age-specific suppression of intracellular calcineurin levels and Ca influx, two critical pathways in T cell activation. Of note, depletion of CD8 T cells did not alter allograft survival outcome in old TAC-treated mice, suggesting that TAC age-specific effects were mainly CD4 T cell mediated. Collectively, our study demonstrates age-specific immunosuppressive capacities of TAC that are CD4 T cell mediated. The suppression of calcineurin levels and Ca influx in both old murine and human T cells emphasizes the clinical relevance of age-specific effects when using TAC.

---

Chemical List

Cytokines|||Immunosuppressive Agents|||Tacrolimus

---

Reference List

World Population Ageing 2013. United Nations, Department of Economic and Social Affairs, Population Division; 2013. ST/ESA/SER.A/348.|||Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR) OPTN/SRTR 2012 Annual Data Report. U.S. Department of Health and Human Services, Health Resources and Services Administration; 2014.|||Watt KDS, Pedersen RA, Kremers WK, Heimbach JK, Sanchez W, Gores GJ. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology. 2009;137:2010–7.|||Karim A, Farrugia D, Cheshire J, Mahboob S, Begaj I, Ray D, et al. Recipient age and risk for mortality after kidney transplantation in England. Transplantation. 2014;97:832–8.|||Blosser CD, Huverserian A, Bloom RD, Abt PD, Goral S, Thomasson A, et al. Age, exclusion criteria, and generalizability of randomized trials enrolling kidney transplant recipients. Transplantation. 2011;91:858–63.|||U.S. Government Accountability Office. Prescription Drugs: FDA Guidance and Regulations Related to Data on Elderly Persons in Clinical Drug Trials. 2007. GAO-07-47R.|||Heinbokel T, Elkhal A, Liu G, Edtinger K, Tullius SG. Immunosenescence and organ transplantation. Transplant Rev (Orlando) 2013;27:65–75.|||Chen G, Lustig A, Weng N-P. T cell aging: a review of the transcriptional changes determined from genome-wide analysis. Front Immunol. 2013;4:121.|||Warrington KJ, Vallejo AN, Weyand CM, Goronzy JJ. CD28 loss in senescent CD4+ T cells: reversal by interleukin-12 stimulation. Blood. 2003;101:3543–9.|||Moro-García MA, Alonso-Arias R, López-Larrea C. When Aging Reaches CD4+ T-Cells: Phenotypic and Functional Changes. Front Immunol. 2013;4:107.|||Saule P, Trauet J, Dutriez V, Lekeux V, Dessaint J-P, Labalette M. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev. 2006;127:274–81.|||Hong MS, Dan JM, Choi J-Y, Kang I. Age-associated changes in the frequency of naïve, memory and effector CD8+ T cells. Mech Ageing Dev. 2004;125:615–8.|||Tullius SG, Milford E. Kidney allocation and the aging immune response. N Engl J Med Massachusetts Medical Society. 2011;364:1369–70.|||Jacobson PA, Schladt D, Oetting WS, Leduc R, Guan W, Matas AJ, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012;12:3326–36.|||Warrington JS, Greenblatt DJ, von Moltke LL. Age-related differences in CYP3A expression and activity in the rat liver, intestine, and kidney. J Pharmacol Exp Ther. 2004;309:720–9.|||Gagnon RC, Peterson JJ. Estimation of confidence intervals for area under the curve from destructively obtained pharmacokinetic data. J Pharmacokinet Biopharm. 1998;26:87–102.|||Bedi DS, Krenzien F, Quante M, Uehara H, Edtinger K, Liu G, et al. Defective CD8 Signaling Pathways Delay Rejection in Older Recipients. Transplantation. 2016;100:69–79.|||Denecke C, Bedi DS, Ge X, Kim IK-E, Jurisch A, Weiland A, et al. Prolonged graft survival in older recipient mice is determined by impaired effector T-cell but intact regulatory T-cell responses. PLoS One. 2010;5:e9232.|||Benichou G, Valujskikh A, Heeger PS. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol. 1999;162:352–8.|||Krieger NR, Yin DP, Fathman CG. CD4+ but not CD8+ cells are essential for allorejection. J Exp Med. 1996;184:2013–8.|||Appay V, Sauce D. Naive T cells: the crux of cellular immune aging? Exp Gerontol. 2014;54:90–3.|||Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28:445–89.|||Tashiro H, Shinozaki K, Yahata H, Hayamizu K, Okimoto T, Tanji H, et al. Prolongation of liver allograft survival after interleukin-10 gene transduction 24–48 hours before donation. Transplantation. 2000;70:336–9.|||Elkhal A, Rodriguez Cetina Biefer H, Heinbokel T, Uehara H, Quante M, Seyda M, et al. NAD(+) regulates Treg cell fate and promotes allograft survival via a systemic IL-10 production that is CD4(+) CD25(+) Foxp3(+) T cells independent. Sci Rep. 2016;6:22325.|||Taub DD, Longo DL. Insights into thymic aging and regeneration. Immunol Rev. 2005;205:72–93.|||Hobbs MV, Ernst DN, Torbett BE, Glasebrook AL, Rehse MA, McQuitty DN, et al. Cell proliferation and cytokine production by CD4+ cells from old mice. J Cell Biochem. 1991;46:312–20.|||Kanno Y, Vahedi G, Hirahara K, Singleton K, O’Shea JJ. Transcriptional and epigenetic control of T helper cell specification: molecular mechanisms underlying commitment and plasticity. Annu Rev Immunol. 2012;30:707–31.|||Halamay KE, Kirkman RL, Sun L, Yamada A, Fragoso RC, Shimizu K, et al. CD8 T cells are sufficient to mediate allorecognition and allograft rejection. Cell Immunol. 216:6–14.|||Krenzien F, ElKhal A, Quante M, Rodriguez Cetina Biefer H, Hirofumi U, Gabardi S, et al. A Rationale for Age-Adapted Immunosuppression in Organ Transplantation. Transplantation. 2015;99:2258–68.|||Frei U, Noeldeke J, Machold-Fabrizii V, Arbogast H, Margreiter R, Fricke L, et al. Prospective age-matching in elderly kidney transplant recipients--a 5-year analysis of the Eurotransplant Senior Program. Am J Transplant. 2008;8:50–7.|||Whisler RL, Beiqing L, Chen M. Age-related decreases in IL-2 production by human T cells are associated with impaired activation of nuclear transcriptional factors AP-1 and NF-AT. Cell Immunol. 1996;169:185–95.|||Haynes L, Linton PJ, Eaton SM, Tonkonogy SL, Swain SL. Interleukin 2, but not other common gamma chain-binding cytokines, can reverse the defect in generation of CD4 effector T cells from naive T cells of aged mice. J Exp Med. 1999;190:1013–24.|||Miller RA. Calcium signals in T lymphocytes from old mice. Life Sci. 1996;59:469–75.|||Pahlavani MA, Vargas DM. Age-related decline in activation of calcium/calmodulin-dependent phosphatase calcineurin and kinase CaMK-IV in rat T cells. Mech Ageing Dev. 1999;112:59–74.|||Haynes L, Eaton SM, Swain SL. The defects in effector generation associated with aging can be reversed by addition of IL-2 but not other related gamma(c)-receptor binding cytokines. Vaccine. 2000;18:1649–53.|||Issa N, Kukla A, Ibrahim HN. Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence. Am J Nephrol. 2013;37:602–12.